Management of Dry Eye - Part 2
Medical Treatment

Volume 33, Number # 3, 2005 Series

1. Calonge M. Dry eye syndrome: Is there any hope for a curative therapy? Arch Soc Espa� Oftalmol 2002:76:119-20.

2. Br�ckner R. Ueber einem Erfolgreich mit Perandren behandelten Fall von Sj�gren�schem Symptomen Komplex. Ophthalmologica 1945;110:37-42.

3. Sullivan DA. Tearful relationships? sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. The Ocular Surface 2004;2:92-123.

4. Pelit A, Bagis T, Kayaselcuk F, et al. Tear function tests and conjunctival impression cytology before and after hormonal replacement therapy in postmenopausal women. Eur J Ophthalmol 2003;13:337-42.

5. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and the prevalence of dry eye syndrome. JAMA 2001;286:2114-9.

6. Liu HB, Loo KK, Palaszynski K, et al. Estrogen receptor _ mediates estrogen�s immune protection disease. J Immunol 2003;171:6936-40.

7. Goebbels M. Tear secretion and tear film function insulin dependent diabetics. Br J Ophthalmol 2000;84:19-21.

8. Rocha EM, Cunha DA, Carneiro EM, et al. Identifica-tion of insulin in the tear film and insulin receptor and IGF-I receptor on the human ocular surface. Invest Ophthalmol Vis Sci 2002; 43:963-7.

9. Markoff E, Lee DW, Fellows KL, et al. Human lacrimal glands synthesize and release prolactin (abstract). Endocrinology 1995;152(suppl):440A.

10. Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998;17:353-8.

11. Markitziu A, Lustmann J, Uzieli B, et al Salivary and lacrimal gland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg Oral Med Oral Pathol 1993;75:418-22.

12. Farpour B, McClellan KA. Diagnosis and management of chronic blepharoconjunctivitis in children. J Pediatr Ophthalmol Strabismus 2002;38:207-12.

13. Sullivan BD, Cermak JM, Sullivan RM, et al: Corre-lations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sj�gren�s syndrome. In Sullivan D. et al (eds) Lacrimal Gland, Tear Film, and Dry Eye Syndrome, Kluwer Academic/Plenum Publishers, 2002, pp. 441-7.

14. Goto E, Endo K, Suzuki A, et al. Tear Evaporation Dynamics in Normal Subjects and Subjects with Obstructive Meibomian Gland Dysfunction. Invest Ophthalmol. Vis. Sci 2003; 44: 533-9.

15. Avramis CA, Wand H, McBride BW, et al. Physical and processing properties of milk, butter and cheddar cheese from cows fed supplemental fish meal. J Dairy Sci 2003;2568-76.

16. Chiu LM, Amsden GW. Current trachoma treatment methodologies: focus on advancements in drug therapy. Drugs. ;62(18):2573-9.

17. McCulley JP, Shine WE. Eyelid disorders: the meibomian gland, blepharitis and contact lenses. Eye Contact Lens 2003;29:S93-5.

18. Derk CT, Vivino FB. A primary care approach to Sj�gren�s syndrome: helping patients cope with sicca symptoms, extraglandular manifestations. Postgrad Med 2004;116:49-59.

19. Price EJ, Rigby SP, Clancy U, Venables PJ. A double, placebo controlled trial of azathioprine in the treatment of primary Sjogren�s syndrome. J Rheumatol. 1998;25:896-9.

20. Fox R, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren�s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996; 5 (suppl 1):S31-36.

21. Thorne JE, Anhalt GJ, Jabs DA. Ocular mucous membrane pemphigoid. Dermatologic Therapy 2002;15:389.

22. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea;2001;20:430-4.

23. McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004;111:796-801

24. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM. Methotrexate in primary Sjogren�s syndrome. Clin Exp Rheumatol. 1996;14:555-8.

25. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56-61.

26. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren�s syndrome: A twelve-week randomized, double blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240-5.

27. Baudouin C. Dry eye: an unexpected inflammatory disease. Arch Soc Espa� Oftalmol 2001;76:205-6.

28. Stern ME, Pflugfelder SC. Inflammation in dry eye. The Ocular Surface 2004;2:124-30.

29. Pflugfleder SC. Anit-inflammatory therapy of dry eye. The Ocular Surface. 1:31-36, 2003.

30. Murube J, Manyari A, ChenZhuo L, et al. Labial salivary gland transplantation in severe dry eye. Oper Techn Oculoplast Orbit Reconstr Surg 1998;1:104-10.
31. Hardy E. Sur la composition du jaborandi. Soc Biol 1875. publicado en C.R. 1876:109-11.

32. Weber A. Die Ursachen des Glaukom. Albrecht von Graefe�s Arch Ophthalmol 1877;23:1.

33. Fleeger CA, editor. USAN 1995. USAN and the USP dictionary of drug names. Rockville, MD: The United States Pharmacopeial Convention, Inc., 1994: 528
34. Vivino FB, Al-Hashimi I, Khan Z. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj�gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;211:358-61

35. Ono M, Takamura E, Shinozaki K,et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren�s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004;138:6-17.

36. Vescovi P, Manfredi M, Cimarosti S. Sjogren�s syndrome: clinical and therapeutic features. A review of the literature. Minerva Stomatol 2004;53:1-19.

37. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sj�gren�s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748-54.

38. Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjogren�s syndrome. Adv Exp Med Biol 2002;506(Pt B):1107-16.

39. Fife RS, et al. Cevimeline for the treatment of xerostomia in patients with Sj�gren�s syndrome. Arch Int Med 2002;162: 1293-300.

40. Impicciattore M, Maraini G, Bertaccini G. Action of eledoisin in human lacrimal secretion in normal and pathological conditions. Naunyn-Schmiedeberg Arch Pharmacol 1973;279:127-31.

41. Appel C. Erfahrungsbericht �ber die Behandlung des Sicca-Syndroms mit Eledoisin-Augentropfen. Klin Monatsbl Augenheilk 1979;175:134.

42. �lvarez MI, Rivas L, Rodr�guez JJ, Murube J. Tratamiento con eledoisina en pacientes con keratoconjunctivitis sicca. Arch Soc Espa� Oftalmol 1996;70:245-52.

43. Botelho SY, Hisida M, Fuenmayor N. Functional innervation of the lacrimal gland in the cat. Arch Ophthalmol 1966;76:581-7.

44. Friedman ZY, Lowe M, Selinger Z. Beta-adrenergic receptor stimulated peroxidase secretion from rat lacrimal gland. Biochem Biophys Acta 1981;675:40-5.

45. Gilbard JP, Rossi SR, Hayda KG, Dartt DA. Stimulation of tear secretion and treatment of dry eye disease with 3-isobutyl-1 methylxantine. Arch Ophthalmol 109:672-6.

46. Peral A. Nucleotides: new therapeutic approach for dry eye treatment. Arch Soc Espa� Oftalmol 2004;79:3-4.

47. Lozatto PA, Pisella PJ, Baudouin C. Phase lipidique du film lacrymal: physiologie et pathologie. J Fr Ophtalmol 2001;24:643-58.

48. Hamano T. Dry eye treatment with eye drops that stimulate mucin production. Adv Exp Med Biol 1998;438:965-8.

49. Jumblatt E, Cunningham L, Jumblat MM. Effects of 15(S)-HETE on human conjunctival mucin secretion.. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 2002), vol 506, pp 323-7.

50. Ubels JL, Aupperlee MD, Jackson RS, et al. Topically applied 15-(S)-HETE stimulates mucin production by corneal epithelium. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 2002), vol 506, pp 317-21.

51. Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs 2004;13:47-54.

52. Lemp MA. Surfacing abnormalities in the preocular tear film and dry eye syndromes. Int Ophthalmol Clin 1973;13:191-9.

53. Murube J. Dacryologia Basica. Madrid: Ed Royper, 1981. pp 510-86.

54. Boyd B, Murube J. What are the main advances in the diagnostic and management of the dry eye. Highlights of Ophthalmology 1993;21:81-8.

55. Murube J, Paterson A, Murube E. Classification of artificial tears. I: Composition and properties, II: Additives. Commercial formulas. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 1998), vol 438, pp 693-715.

56. ChenZhuo L, Murube J, Latorre A, et al. Different concentrations of amino acids in tears of normal and human dry eye. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 2002), vol 506, pp 617-21.

57. van Setten G.Inmuno-dacryochemistry (immunoferning): a new screening method for proteins in tears. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 2002), vol 506, pp 611-5.

58. Roth HW. Zur Therapie des trockenen Auges am Arbeitsplatz mit Liposomen. Die BG 1996;22:1-3.

59. Korb DR. Alleviation of computer-induced eye discomfort syndrome and associated lipid layer changes. In Sullivan DE, et al.(eds.). Lacrimal gland, tear film, and dry eye syndromes 3. (Adv Exp Med Biol. New York:Kluver/Plenum 2002), pp 501-12.

60. Mastman GJ, Baldes EJ, Henderson JW. The total osmotic pressure of tears in normal and various pathologic conditions. Arch Ophthalmol 1961:65: 509-13.

61. Gilbard JP, Harris RL, Santamaria J. Osmolarity of tear microvolumes in keratoconjunctivitis sicca. Arch Ophthalmol 1978;96:677-81.

62. Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren�s syndrome patients. Br J Ophthalmol 2002;86:879-84.

63. Cantonnet A.. Formules de collyres isotoniques aux larmes. Arch Ophtalmol (Paris) 1908 ;28:617-21.

64. Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. Exp Eye Res 1971;11:239-50.

65. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol 1995; 113:1266-70.

66. Ubels JL, Williams KK, L�pez Bernal D, Edelhauser HF. Evaluation of effects of a physiologic artificial tear on the corneal epithelial barrier: electrical resistance and carboxyfluorescein permeability. In Sullivan DA. Lacrimal Gland, Tear Film, and Dry Eye Syndromes. Nee York:Plenum Press. 1994, pp 441-52.

67. Verkman AS. Role of aquaporin water channels in eye function- Exp Eye Res 2003;2003:76:137-43.

68. McDermott AM. Defensins and other antimicrobial peptides at the ocular surface. The Ocular Surface 2004; 2:229-47

69. Holly FJ. Vitamins and polymers in the treatment of ocular surface disease. Contact Lens Spectrum 1990;1:37.

70. Tsubota K. Understanding dry eye syndrome. In Sullivan et al (eds), New York:Plenum Press, (Adv Experimental Medicine and Biol 2002), vol 506, pp 2-16.

71. Holly, F.J. and Holly, T.F.: Advances in ocular tribology. In: Sullivan DA, et al (ed). Lacrimal Gland, Tear Film, and Dry Eye Syndromes, New York: Plenum Press, 1994, pp. 275.

72. Hamilton JB. Keratitis sicca including Sj�gren�s s�ndrome. Trans Ophthalmol Soc Austral 1940;2:63. Ref in Brit J Ophthalmol 1942;26:280-1.

73. Bisantis C. Diagnostica delle malattie oculari da alterata secrezione lacrimale. Presentazione di una scheda clinica. Boll Ocul 1976-8 (Suppl 57):23-39.

74. Tsubota K, Goto E, Fujita H et al. Treatment of dry eye by autologous serum application in Sj�gren�s syndrome. Br J Ophthalmol 1999;83:390-5.

75. Poon AC, Geerling G, Dart JKG, et al.. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85: 1188-97.

76. Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders- Br JOphthalmol 2004;88:1467-74.

77. M�ndez Fern�ndez R. R, Ben�tez del Castillo JM. Suero ant�logo. In: Ben�tez del Castillo et al. Superficie ocular. Madrid:Ed. Sociedad Espa�ola de Oftalmolog�a 2004. pp 307-14.

78. Hartwig D, Harloff S, Liu L, et al. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects?. Transfusion 2004;44:1724-31.

79. Filatov VP, Chevaljev VE. Surgical treatment of the parenchimoatous xerosis (in Rusish) J Oftalmol(Odessa) 1951;3:131-7.

80. Murube J. Transplantation of salivary gland to the lacrimal basin�. Scand J Rheumatol. 1986;Suppl.61:264-7.

81. Geerling G, Sieg P, Bastian GO. Laqua H. Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca. Ophthalmology 1998;105:327-35.

82. Murube J. Saliva aut�loga en colirio para superficie ocular. Bol Soc Oftalmol Madrid 2003;42:10-2.

83. Gipson IK, Hori Y, Arg�eso P. Charac-ter of ocular surface mucins and their alteration in dry eye disease. The Ocular Surface 2004:2: 131-48.

84. Knop N, Knop E. Conjunctiva-associated lymphoid tissue ihn the human eye. IOVS 2000;41:1270-9.